Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib + sintilimab adjuvant therapy after surgery for high-risk hepatocellular carcinoma
ChiCTR2400090460Phase 3Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of donafenib and sintilimab in hepatocellular carcinoma (HCC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Percentage of recurrence-free patients at 1 year. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
donafenibsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400090460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090460.